KLK3 and posterior cortical atrophy: AMACR could avoid 58.6% of unnecessary biopsies in the validation cohort, which was significantly higher than 26.3% in PSA, with only 10 (7.5%) patients missed, among which 9 (6.8%) of these patients had clinically significant PCa.